Glioblastoma Brain Tumor Insights and Advances

Published

Table of Contents

Glioblastoma multiforme or glioom hersenen represents one of the most aggressive primary brain tumors with a complex interplay of genetic mutations and microenvironmental factors driving its progression. Classified as a World Health Organization Grade IV malignancy, this tumor exhibits rapid growth and resistance to conventional therapies, posing significant challenges in clinical management. Understanding its biological origins—including key mutations in TP53, PTEN, EGFR, and IDH1/2—is critical for developing targeted interventions, while its heterogeneous nature demands a multidisciplinary approach encompassing surgery, radiotherapy, and emerging immunotherapies. The tumor microenvironment, characterized by hypoxia and angiogenesis, further complicates treatment strategies, necessitating innovative solutions to overcome the blood-brain barrier and improve patient outcomes.

Diagnosis of glioblastoma hinges on advanced imaging techniques such as contrast-enhanced MRI and histopathological confirmation through biopsy, though current methods face limitations in detecting non-enhancing lesions or distinguishing primary GBM from metastatic disease. Treatment modalities range from standard protocols involving maximal safe resection and temozolomide chemotherapy to experimental therapies like TTFields and CAR-T cell immunotherapy, each with distinct efficacy profiles and adverse effects. Prognostic factors such as MGMT methylation status and IDH mutations significantly influence survival rates, underscoring the need for personalized medicine in managing this devastating condition.

Glioom Hersenen

Glioblastoma Multiforme (Glioblastoma): Biological Origins and Pathogenic Mechanisms

Glioblastoma multiforme (GBM), classified as a World Health Organization (WHO) Grade IV astrocytoma, represents the most aggressive and lethal form of primary brain tumor in adults. Its biological complexity arises from a combination of intrinsic genetic alterations, dysregulated cellular pathways, and a highly immunosuppressive tumor microenvironment. Unlike lower-grade gliomas, GBM exhibits rapid progression, diffuse infiltration of surrounding brain tissue, and resistance to conventional therapies, necessitating a comprehensive understanding of its pathogenesis.

The tumor’s origins trace back to neural stem cells (NSCs) or progenitor cells in the brain, where cumulative genetic and epigenetic mutations disrupt normal cellular homeostasis. Key driver mutations, including TP53 (cell cycle regulation), PTEN (PI3K/AKT pathway), EGFR (epidermal growth factor receptor amplification), and IDH1/2 (isocitrate dehydrogenase mutations), collectively contribute to uncontrolled proliferation, genomic instability, and therapeutic resistance. Below follows a structured analysis of these mechanisms and their clinical implications.

Genetic and Molecular Pathways in GBM Progression

The progression of GBM is governed by sequential and parallel molecular alterations that converge on critical cellular processes: proliferation, angiogenesis, invasion, and immune evasion. The following pathways represent the primary drivers of GBM pathogenesis:
  1. Cell Cycle Dysregulation and Apoptosis Evasion
    The TP53 tumor suppressor gene, mutated in ~30% of primary GBM cases, disrupts cell cycle checkpoints and DNA repair mechanisms. Loss of functional p53 protein leads to genomic instability, resistance to apoptosis, and accumulation of further mutations. In contrast, secondary GBM (arising from lower-grade gliomas) frequently retains TP53 mutations early in progression, while primary GBM often exhibits CDKN2A/B deletions (encoding p16^INK4a^ and p14^ARF^), further accelerating cell cycle progression.
    Key Mutation: TP53 (30% primary GBM) vs. TP53 + ATRX/DAXX (secondary GBM progression).
  2. PI3K/AKT/mTOR Hyperactivation
    The PTEN tumor suppressor, inactivated in ~40% of GBM cases, negatively regulates the PI3K/AKT pathway. Loss of PTEN results in constitutive activation of AKT, promoting cell survival, metabolism, and resistance to radiotherapy. Amplification of EGFR (observed in ~40% of GBM) further exacerbates this pathway, often via EGFRvIII, a truncated, constitutively active receptor variant that enhances tumor growth and invasion.
    Pathway Interaction: PTEN loss + EGFR amplification → Synergistic PI3K/AKT activation with therapeutic implications for mTOR inhibitors.
  3. IDH1/2 Mutations and Epigenetic Reprogramming
    Mutations in IDH1 (R132H) or IDH2 (R172K), present in ~10% of primary GBM but ~90% of secondary GBM, catalyze the production of 2-hydroxyglutarate (2-HG), an oncometabolite that inhibits DNA/RNA demethylation. This leads to hypermethylation of tumor suppressor genes and a distinct CpG island methylator phenotype (G-CIMP), associated with improved prognosis in lower-grade gliomas but less favorable outcomes in secondary GBM progression.
    Epigenetic Shift: IDH1/2 mutations → 2-HG accumulation → DNA hypermethylation → Therapeutic vulnerability to IDH inhibitors.
  4. RB Pathway Disruption
    Mutations or deletions in CDKN2A/B (encodes p16^INK4a^ and p14^ARF^) or RB1 (retinoblastoma protein) occur in ~70% of GBM, bypassing the G1/S checkpoint and enabling uncontrolled proliferation. This pathway is frequently altered in primary GBM alongside EGFR amplification, whereas secondary GBM often retains RB1 function longer during progression.

Comparative Analysis: Primary vs. Secondary Glioblastoma

Primary and secondary GBM exhibit distinct genetic, demographic, and prognostic profiles, reflecting their divergent origins. The following table summarizes key differences:
Criteria Primary Glioblastoma (De Novo) Secondary Glioblastoma (Progressive)
Age of Onset Peak incidence in 65–70 years; rare in patients <45. Typically arises from lower-grade gliomas (WHO Grade II/III); median age 45–50 years.
Genetic Markers
  • TP53 mutations (~30%), PTEN loss (~40%), EGFR amplification (~40%), CDKN2A/B deletion (~70%).
  • Mesenchymal subtype dominant (high NF1 mutations, MET amplification).
  • IDH1/2 wild-type in ~90% of cases.
  • TP53 mutations (~70%), IDH1/2 mutations (~90%), ATRX/DAXX loss (~70%).
  • Proneural subtype dominant (high PDGFRA mutations).
  • G-CIMP phenotype common (hypermethylation).
Prognosis Median survival 12–15 months post-diagnosis; 5-year survival <5%. Median survival 18–24 months; 5-year survival ~10–15% (better response to temozolomide).
Treatment Resistance
  • High stem-like cell populations (CD133+, SOX2+).
  • BBB disruption with heterogeneous vascularization.
  • Intrinsic DNA repair proficiency (MGMT promoter methylation variable).
  • IDH1/2 mutations confer sensitivity to IDH inhibitors (e.g., ivosidenib).
  • MGMT promoter methylation (~80%) predicts better response to temozolomide.
  • Slower proliferation rate but persistent invasive growth.

The Tumor Microenvironment in GBM: Hypoxia, Angiogenesis, and Therapeutic Barriers

The tumor microenvironment (TME) of GBM is a dynamic ecosystem that facilitates tumor progression, immune evasion, and resistance to therapies. Three critical components—hypoxia, angiogenesis, and the blood-brain barrier (BBB)—create a hostile environment for both tumor cells and therapeutic interventions.
  1. Hypoxia and Metabolic Adaptation
    GBM exhibits pathological hypoxia due to rapid cell proliferation outpacing vascular supply. Hypoxia-inducible factor 1-alpha (HIF-1α) stabilizes under low oxygen conditions, upregulating:
    • Vascular endothelial growth factor (VEGF), promoting angiogenesis.
    • Carbonic anhydrase IX (CAIX), acidifying the TME and enhancing invasion.
    • Autophagy pathways, enabling survival under metabolic stress.
    Hypoxia Paradox: While VEGF inhibitors (e.g., bevacizumab) reduce edema, they may normalize vasculature temporarily, improving drug delivery but also selecting for more aggressive, hypoxia-adapted clones.
  2. Glioom Hersenen - Ilustrasi 2

    Symptoms and Diagnostic Procedures – Clinical Manifestations in Glioblastoma Multiforme

    Glioblastoma multiforme (GBM) presents with a heterogeneous spectrum of neurological symptoms that vary depending on tumor location, size, and rate of progression. Early-stage manifestations are often non-specific, mimicking other neurological or psychiatric conditions, while late-stage symptoms reflect mass effect, infiltration, and systemic complications. Diagnostic accuracy relies on a multimodal approach integrating clinical presentation, advanced neuroimaging, histopathological confirmation, and molecular profiling. This section categorizes symptoms by anatomical involvement and delineates the step-wise diagnostic workflow, including limitations and critical decision points.

    Neurological Symptoms by Tumor Location and Progression Stage

    The clinical presentation of GBM is dictated by its anatomical origin, with distinct patterns emerging in early (weeks to months) and late (months to years) stages. Early symptoms typically reflect focal dysfunction, whereas late-stage manifestations involve generalized neurological decline due to tumor burden, edema, or hydrocephalus.

    Early-Stage Symptoms (Focal Dysfunction)
    Early GBM often presents with symptoms localized to the affected lobe or structure, though rapid progression may obscure initial patterns. Key manifestations include:

    - Frontal Lobe Involvement
    GBM in the frontal lobe frequently manifests as subtle personality changes, including apathy, disinhibition, or executive dysfunction (e.g., impaired judgment, poor impulse control). Motor deficits such as contralateral hemiparesis or gait ataxia may develop due to corticospinal tract involvement. Clinical examples include:

  3. A 55-year-old patient presenting with sudden emotional lability and neglect of left-sided stimuli, later diagnosed with a right frontal GBM.
  4. Progressive Broca’s aphasia (non-fluent speech) in left frontal tumors, initially misattributed to stroke.
  5. - Temporal Lobe Involvement
    Seizures are the most common early symptom in temporal GBM, often focal aware seizures (formerly simple partial) with aurae (e.g., olfactory hallucinations, déjà vu). Memory deficits and Wernicke’s aphasia (fluent but nonsensical speech) may occur in left temporal tumors. Examples:

  6. A 42-year-old with recurrent gustatory seizures (metallic taste) and dreamy states, later identified as a left temporal GBM.
  7. Complex partial seizures with automatisms (lip-smacking, fumbling movements) in non-dominant temporal lesions.
  8. - Parietal Lobe Involvement
    Early symptoms include sensory deficits (e.g., numbness, astereognosis) and visuospatial neglect (right parietal). Gerstmann’s syndrome (finger agnosia, acalculia, left-right disorientation) may emerge in dominant parietal tumors. Clinical cases:

  9. A 60-year-old with progressive left-sided numbness and difficulty reading maps, diagnosed with a right parietal GBM.
  10. Contralateral sensory loss with preserved motor function, initially attributed to peripheral neuropathy.
  11. - Occipital Lobe Involvement
    Visual field deficits (homonymous hemianopia) and visual hallucinations (e.g., formed images, scintillating scotomas) are hallmark features. Examples:

  12. A 50-year-old reporting sudden loss of right visual field with photopsias, later confirmed as an occipital GBM.
  13. Palinopsia (persistent visual trailing) in bilateral occipital involvement.
  14. - Brainstem/Cerebellar Involvement
    Cranial nerve palsies (e.g., CN III, VII), ataxia, and long-tract signs (e.g., spasticity) dominate. Brainstem GBM may present with locked-in syndrome in advanced stages. Cases:

  15. A 48-year-old with diplopia (CN III palsy) and facial numbness (CN V), progressing to quadriparesis, diagnosed with a pontine GBM.
  16. Truncal ataxia and nystagmus in cerebellar GBM, initially misdiagnosed as multiple sclerosis.
  17. Late-Stage Symptoms (Generalized Neurological Decline)
    As GBM progresses, symptoms reflect mass effect, increased intracranial pressure (ICP), and systemic complications:

  18. Raised ICP: Headache (worse on awakening), papilledema, nausea/vomiting, and cognitive decline (e.g., confusion, lethargy).
  19. Hydrocephalus: Gait instability, urinary incontinence, and dementia-like symptoms due to obstructive or communicating hydrocephalus.
  20. Seizure progression: From focal to generalized tonic-clonic seizures or status epilepticus.
  21. Endocrine dysfunction: Diabetes insipidus (hypothalamic involvement), SIADH, or adrenal insufficiency in pituitary stalk compression.
  22. Systemic complications: Cachexia, hypercalcemia (paraneoplastic), or DIC in terminal stages.
  23. Diagnostic Procedures for Glioblastoma Multiforme

    Diagnosis of GBM requires a multidisciplinary approach, combining clinical suspicion, neuroimaging, histopathological analysis, and molecular characterization. The workflow prioritizes non-invasive imaging followed by invasive confirmation and genomic profiling to guide therapy.

    Step 1: Neuroimaging – Suspicion and Characterization
    Neuroimaging is the first-line tool for GBM diagnosis, with MRI providing superior soft-tissue contrast compared to CT. Key techniques include:

    - Contrast-Enhanced MRI (Gadolinium)

  24. T1-weighted post-contrast images reveal heterogeneous enhancement with ring-like or nodular patterns, often with central necrosis (non-enhancing core).
  25. Peritumoral edema (T2/FLAIR hyperintensity) is extensive, distinguishing GBM from low-grade gliomas.
  26. Example: A 65-year-old with rapidly progressive left hemiparesis shows a right frontal mass with irregular ring enhancement and surrounding vasogenic edema on MRI.
  27. - Diffusion Tensor Imaging (DTI)

  28. Maps white matter tracts, aiding in surgical planning by delineating tumor infiltration from preserved fibers.
  29. Useful in non-enhancing GBM (e.g., IDH-wildtype) where conventional MRI may underestimate extent.
  30. - Perfusion-Weighted Imaging (PWI)

  31. Relative cerebral blood volume (rCBV) >1.75–2.0 mL/100g suggests high-grade glioma, though not specific to GBM.
  32. Example: A high rCBV in a temporal lesion supports GBM over metastasis.
  33. - MR Spectroscopy (MRS)

  34. Elevated choline (Cho) and reduced N-acetylaspartate (NAA) ratios indicate high cellular turnover.
  35. Lipid-lactate peaks suggest necrosis, common in GBM.
  36. Step 2: Histopathological Confirmation
    Biopsy or surgical resection remains the gold standard for diagnosis, with immunohistochemistry (IHC) and molecular testing integrated into the workflow.

    - Surgical Biopsy vs. Resection

  37. Biopsy: Preferred in eloquent cortex or brainstem GBM where resection risks morbidity.
  38. Resection: Maximal safe resection (e.g., awake craniotomy for language mapping) improves survival and reduces recurrence.
  39. Example: A frontal GBM in a patient with Broca’s area involvement may require intraoperative mapping to preserve speech.
  40. - Key Histopathological Features

  41. Pseudopalisading necrosis (pathognomonic, though not exclusive to GBM).
  42. Microvascular proliferation (glomeruloid vessels).
  43. High mitotic activity (>20 mitoses/10 HPF).
  44. - Immunohistochemistry (IHC) Markers

  45. IDH1-R132H mutation: Positive in ~90% of secondary GBM (IDH-mutant) but rare in primary GBM (IDH-wildtype).
  46. ATRX loss: Associated with IDH-mutant GBM and alternative lengthening of telomeres (ALT).
  47. p53 overexpression: Common in IDH-wildtype GBM.
  48. MGMT promoter methylation: Predicts response to temozolomide.
  49. Step 3: Molecular Profiling and Next-Generation Sequencing (NGS)
    Molecular characterization distinguishes primary (IDH-wildtype) from secondary (IDH-mutant) GBM, influencing prognosis and therapy:

    - IDH1/2 Mutation Status

  50. IDH-mutant GBM: Slower progression, better response to chemoradiotherapy, median survival ~31 months.
  51. IDH-wildtype GBM: Aggressive, median survival ~15 months, TERT promoter mutations common.
  52. - TERT Promoter Mut

    Glioom Hersenen - Ilustrasi 3

    Treatment Modalities – Standard and Experimental Approaches in Glioblastoma Multiforme

    Glioblastoma multiforme (GBM) remains one of the most aggressive primary brain tumors, with a median survival of approximately 14–16 months under standard-of-care (SOC) treatment. The therapeutic landscape combines maximal safe resection, radiotherapy (RT), and temozolomide (TMZ)-based chemotherapy, supplemented by emerging experimental strategies targeting tumor heterogeneity, immune evasion, and metabolic vulnerabilities. While SOC improves progression-free survival (PFS) and overall survival (OS), resistance mechanisms and tumor recurrence necessitate adaptive, multimodal approaches. Experimental therapies—including TTFields (Tumor Treating Fields), cellular immunotherapies (e.g., CAR-T), oncolytic viruses, and targeted small-molecule inhibitors—are under rigorous evaluation in clinical trials, with select agents demonstrating modest but meaningful improvements in select patient subsets. Below, the standard treatment paradigm is detailed alongside emerging experimental modalities, followed by a hypothetical multimodal protocol integrating surgery, radiotherapy, and immunotherapy.

    Standard-of-Care Treatment: Surgery, Radiotherapy, and Temozolomide Chemotherapy

    Maximal Safe Surgical Resection
    Surgical intervention in GBM aims to achieve gross total resection (GTR) when feasible, defined as removal of ≥98% of contrast-enhancing tumor on postoperative MRI. Studies demonstrate that GTR correlates with improved PFS and OS, with median survival extending to 20–24 months in select patients, compared to 12–15 months with subtotal resection (STR). However, surgical morbidity (e.g., neurological deficits, epilepsy) and tumor location (e.g., eloquent cortex) often limit aggressive resection. Intraoperative 5-aminolevulinic acid (5-ALA)-induced fluorescence and neuronavigation systems enhance resection precision by differentiating tumor tissue from normal brain.

    Fractionated Radiotherapy
    Postoperative external beam radiotherapy (EBRT) is administered at 60 Gy in 30 fractions (2 Gy/fraction) over 6 weeks, targeting the gross tumor volume (GTV) + 2–3 cm margin to account for microscopic infiltration. Hypofractionated schedules (e.g., 40 Gy in 15 fractions) are being explored for elderly or frail patients, though data suggest non-inferior OS but higher local recurrence rates. Concurrent TMZ during RT enhances radiosensitivity via O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, a key prognostic biomarker.

    Temozolomide Chemotherapy
    TMZ, an oral alkylating agent, is administered concurrently with RT (75 mg/m²/day), followed by adjuvant therapy (150–200 mg/m²/day for 5 days every 28 days). MGMT promoter methylation predicts higher response rates to TMZ, with 6-month PFS rates of ~45% in methylated tumors vs. ~15% in unmethylated cases. Dose-limiting toxicities include myelosuppression (thrombocytopenia, neutropenia) and hepatotoxicity, though prophylactic antiemetics and dose adjustments mitigate risks.

    Response Metrics and Prognostic Factors

  53. Radiographic response: Assessed via RANO criteria, with complete response (CR) rare and partial response (PR) observed in ~30–40% of patients post-SOC.
  54. MGMT methylation: Strongest prognostic factor, with methylated tumors exhibiting median OS of 21 months vs. 12 months in unmethylated cases.
  55. IDH1/2 mutation: Present in ~10% of GBMs, associated with better prognosis (median OS ~31 months) and higher chemosensitivity.
  56. Emerging Experimental Therapies: Clinical Trial Landscape and Mechanistic Insights

    Despite SOC advances, GBM recurrence is inevitable, necessitating novel therapeutic strategies targeting tumor heterogeneity, immune evasion, and metabolic reprogramming. Below, a comparative table summarizes key experimental therapies in clinical trials, focusing on phase, response rates, and adverse effects.
    Therapy Mechanism Clinical Trial Phase Response Rate (ORR/PFS/OS) Common Adverse Effects Key Limitations
    TTFields (Optune®) Disrupts mitotic spindle formation via low-intensity, alternating electric fields (200 kHz) targeting dividing cells. Phase III (EF-14)
    • EF-14: 6-month OS 43% (TTFields + SOC) vs. 31% (SOC alone); median OS 20.9 vs. 15.6 months.
    • TTFields + TMZ: PFS benefit in MGMT-methylated tumors.
    • Skin irritation (93%), headache (50%), fatigue (30%).
    • Requires ≥18 hours/day adherence.
    No survival benefit in unselected populations; efficacy dependent on tumor cell cycle phase.
    CAR-T Cells (e.g., CT053, CT043) Engineered T-cells targeting EGFRvIII or IL13Rα2 (overexpressed in GBM). Phase I/II (CT053: NCT02664363)
    • CT053 (EGFRvIII-CAR-T): 1-year OS 72% in EGFRvIII-positive patients; PFS 20% at 6 months.
    • CT043 (IL13Rα2-CAR-T): PFS 46% at 6 months (vs. 15% in controls).
    • Cytokine release syndrome (CRS, 30%), neurotoxicity (15%), tumor lysis syndrome.
    • Limited by immune suppression in GBM microenvironment.
    Antigen escape (loss of EGFRvIII/IL13Rα2 expression); off-target effects in normal brain tissue.
    Oncolytic Viruses (e.g., DNX-2401, PVS-RIPO) Replicating viruses (e.g., HSV-1-based DNX-2401) lyse tumor cells and induce antitumor immunity. Phase III (DNX-2401: NCT03213544)
    • DNX-2401 + SOC: Median OS 11.8 months (vs. 9.6 months in SOC alone); 6-month OS 51% vs. 38%.
    • PVS-RIPO: PFS benefit in recurrent GBM (Phase II).
    • Fever (80%), headache (60%), transient neurological symptoms.
    • Risk of viral shedding (containment protocols required).
    Limited by pre-existing immunity to viral vectors; optimal dosing schedules not yet defined.
    Checkpoint Inhibitors (e.g., Nivolumab, Pembrolizumab) Blockade of PD-1/PD-L1 to restore T-cell-mediated antitumor immunity. Phase III (CheckMate 498: NCT02667587)
    • CheckMate 498: Median

      Prognostic Factors and Quality of Life in Glioblastoma Multiforme: Patient Outcomes and Long-Term Management

      Glioblastoma multiforme (GBM) remains one of the most aggressive primary brain tumors, with heterogeneous clinical trajectories influenced by molecular, demographic, and therapeutic factors. Prognostic stratification in GBM is critical for personalized treatment planning, patient counseling, and quality-of-life (QoL) optimization. While median overall survival (OS) for standard-treated GBM patients ranges between 12–15 months, molecular subtypes—particularly isocitrate dehydrogenase (IDH)-mutant GBM—demonstrate markedly improved outcomes, including prolonged survival and better functional preservation. Concurrently, the progressive nature of GBM induces multifaceted declines in physical, cognitive, and psychosocial domains, necessitating structured palliative and supportive care frameworks. This section examines the key prognostic determinants, trajectories of symptom progression, and evidence-based strategies for QoL enhancement, alongside structured long-term follow-up protocols for survivors.

      Key Prognostic Factors in Glioblastoma Multiforme

      Prognostic factors in GBM are categorized into demographic, clinical, molecular, and treatment-related variables, each contributing independently or synergistically to survival and functional outcomes. The most clinically validated factors include:

      - Age at Diagnosis
      Younger patients (<50 years) exhibit superior survival compared to older adults, with median OS of 18–24 months versus 8–12 months in those ≥70 years. Age-related declines in neuroplasticity, immune competence, and tolerance to aggressive therapies (e.g., temozolomide, radiotherapy) contribute to poorer outcomes. However, performance status (PS) often mediates age-related disparities, with frail elderly patients faring worse than robust counterparts.

      - Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group (ECOG) Scale
      KPS ≥70 correlates with median OS of 14–18 months, while KPS <60 reduces survival to 4–6 months. The ECOG scale (0–4) similarly stratifies patients, with ECOG 0–1 associated with better tolerance to multimodal therapy. Preoperative KPS is particularly prognostic, as rapid decline post-diagnosis (e.g., due to mass effect or edema) portends worse trajectories.

      - O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation Status
      MGMT methylation, occurring in 30–45% of GBM cases, predicts sensitivity to temozolomide via impaired DNA repair. Methylated tumors achieve median OS of 21 months versus 12–15 months in unmethylated counterparts. Combined with radiotherapy, MGMT methylation confers a ~50% reduction in mortality risk (HR: 0.5, p < 0.001). However, its prognostic value diminishes in IDH-wildtype GBM, where other genomic alterations (e.g., TP53, EGFR amplification) dominate.

      - Isocitrate Dehydrogenase (IDH) Mutation Status
      IDH-mutant GBM (10% of cases) represents a distinct clinical entity with median OS exceeding 3 years, compared to 14–15 months in IDH-wildtype tumors. Key features include:

    • Younger age at onset (median: 45 years vs. 64 years).
    • Secondary GBM phenotype, often arising from lower-grade gliomas (e.g., astrocytoma grade II/III).
    • Better response to chemotherapy (e.g., temozolomide, PCV regimens).
    • Lower proliferative index and higher sensitivity to differentiation therapy (e.g., histone deacetylase inhibitors).
    • Mutational profiling via next-generation sequencing (NGS) is now standard, with IDH1 R132H being the most common mutation (detectable via immunohistochemistry).
      Prognostic Stratification Example (WHO CNS5 Classification):
    • IDH-wildtype GBM (G4): Median OS 12–15 months; poor response to standard therapy.
    • IDH-mutant GBM (G3): Median OS >36 months; potential for long-term survival with adjuvant therapy.
    • IDH-mutant, MGMT-methylated GBM: Best prognosis subgroup (OS ~5 years with aggressive management).
    • Trajectories of Physical and Cognitive Decline in GBM Patients

      GBM progression and treatment-induced toxicities converge to produce heterogeneous but predictable patterns of decline, stratified by tumor location, molecular subtype, and therapeutic interventions. Physical and cognitive deficits often emerge within 3–6 months post-diagnosis, with accelerated deterioration in IDH-wildtype GBM.

      - Motor and Neurological Deficits
      Tumor location dictates symptom onset:

    • Frontal lobe involvement: Early executive dysfunction, apathy, or disinhibition (e.g., pseudobulbar affect).
    • Temporal lobe tumors: Epilepsy (60–80% of cases), memory impairment (hippocampal compression), and auditory hallucinations.
    • Parietal lobe: Contralateral hemiparesis, sensory neglect, and apraxia.
    • Brainstem/cerebellar GBM: Cranial nerve palsies (e.g., CN VII, VI), ataxia, and rapid decline due to mass effect.
    • Treatment-related motor deficits include:
    • Radiation necrosis (6–12 months post-RT), presenting as progressive focal weakness.
    • Corticosteroid-induced myopathy (prednisone >40 mg/day for >3 months).
    • - Cognitive Decline and Neuropsychiatric Symptoms
      Executive dysfunction (working memory, planning) and processing speed deficits are universal, with 70–90% of patients demonstrating impairment within 6 months. Specific patterns include:

    • Dysexecutive syndrome: Poor initiation, perseveration, and impaired judgment (frontal lobe).
    • Anterograde amnesia: Hippocampal compression or temporal lobe infiltration.
    • Visuospatial neglect: Right parietal tumors.
    • Neuropsychiatric manifestations (30–50% of patients) include:
    • Pseudobulbar affect (emotional lability due to corticobulbar tract disruption).
    • Depression (50% prevalence), often underdiagnosed due to overlap with tumor-related fatigue.
    • Anxiety and agitation, exacerbated by steroid tapering or tumor progression.
    • - Fatigue and Systemic Symptoms
      Neurogenic fatigue (80% of patients) arises from hypothalamic/pituitary dysfunction or cytokine release. Anemia (Hb <10 g/dL) and elevated inflammatory markers (e.g., CRP, IL-6) correlate with worse QoL. Cachexia develops in 20–30% of terminal patients, driven by hypermetabolism and treatment side effects (e.g., temozolomide-induced nausea).

      Palliative and Supportive Care Strategies for GBM Patients

      Palliative care in GBM focuses on symptom mitigation, functional preservation, and psychosocial support, with integration of neuro-oncology-specific protocols. Early referral (<3 months post-diagnosis) improves survival and QoL, reducing hospitalizations by 30–40%.

      - Neurocognitive Rehabilitation
      Multidisciplinary approaches include:

    • Cognitive remediation therapy: Computerized programs (e.g., CogniFit, Lumosity) for attention and memory.
    • Occupational therapy: Adaptive strategies for activities of daily living (ADLs), e.g., compensatory techniques for hemiparesis.
    • Speech-language pathology: Aphasia management (left hemisphere tumors) and dysphagia screening (post-surgery).
    • Evidence-based interventions:
    • Donepezil (5–10 mg/day) for mild cognitive impairment (Level B evidence).
    • Methylphenidate for fatigue-related cognitive slowing (off-label).
    • - Pain and Symptom Management
      Neuropathic pain (e.g., trigeminal neuralgia, radicular pain) requires:

    • First-line: Gabapentin (300–3600 mg/day) or pregabalin (titrated to effect).
    • Second-line: Low-dose tramadol or carbamazepine (for lancinating pain).
    • Headache management:
    • Acute: IV dexamethasone (4–16 mg/day) + NSAIDs (e.g., ketorolac).
    • Chronic: Topiramate (25–100 mg/day) for steroid-induced headaches.
    • Dysphagia/pseudobulbar affect:
    • Dextromethorphan/quinidine (Nuedexta) for emotional lability (FDA-approved).
    • - Psychological and Spiritual Support
      Anxiety/de

      Glioblastoma multiforme remains a formidable challenge in neuro-oncology, yet advancements in molecular profiling and targeted therapies offer hope for improved patient stratification and treatment optimization. While standard-of-care approaches provide temporary control, emerging strategies—including oncolytic viruses and immune checkpoint inhibitors—hold promise for extending survival and enhancing quality of life. Addressing the tumor microenvironment and refining diagnostic precision are pivotal steps toward refining therapeutic paradigms. Ultimately, a holistic approach integrating palliative care, neurocognitive rehabilitation, and psychological support is essential to mitigate the physical and emotional toll of this disease, ensuring patients receive comprehensive care tailored to their unique needs.